Cancer Chemotherapy and Pharmacology最新文献

筛选
英文 中文
An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib. 支持新型 AKT 抑制剂 capivasertib 剂量的暴露安全性分析。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-28 DOI: 10.1007/s00280-025-04775-8
Carlos Fernandez Teruel, Marie Cullberg, Ignacio González-García, Gaia Schiavon, Diansong Zhou
{"title":"An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.","authors":"Carlos Fernandez Teruel, Marie Cullberg, Ignacio González-García, Gaia Schiavon, Diansong Zhou","doi":"10.1007/s00280-025-04775-8","DOIUrl":"10.1007/s00280-025-04775-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate capivasertib exposure-response relationships for clinical safety events to support dosage selection.</p><p><strong>Methods: </strong>Data from 277 patients with solid tumors participating in three phase 1 studies were analyzed. Capivasertib 80-800 mg was administered as monotherapy orally twice daily (BID) on continuous or intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) schedules. Relationships between exposure related metrics (dose, weekly dose, AUC, AUC<sub>PWD</sub>, C<sub>max</sub>, and C<sub>min</sub>) and probability of safety endpoints (adverse event [AE] leading to dose discontinuation, AE leading to dose modification, serious AE [SAE], AE grade ≥ 3, AE grade ≥ 1, diarrhea AE grade ≥ 2, rash AE grade ≥ 2, hyperglycemia AE grade ≥ 3 and increased blood glucose > 13.9 mmol/L) were evaluated by logistic regression.</p><p><strong>Results: </strong>Significant exposure-response relationships were identified for all safety endpoints evaluated, except for AE grade ≥ 1. The analysis suggested that most of the safety endpoints are driven by the total weekly exposure, whereas glucose elevations are driven by the exposure achieved within a dosing interval. The probability of experiencing an AE leading to dose discontinuation, AE leading to dose modification, SAE, AE grade ≥ 3, diarrhea or rash were lower with the 480 mg BID [4/3] schedule than with the 320 mg BID continuous schedule.</p><p><strong>Conclusion: </strong>Significant exposure-response relationships were identified for safety endpoints when capivasertib was administered to patients with solid tumors suggesting that the intermittent [4/3] schedule is better tolerated than the continuous schedule due to lower total weekly exposure.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"48"},"PeriodicalIF":2.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations- a randomized study evaluated in a tumour-free porcine model. 反复给药和连续给药阿霉素对骨和软组织浓度的影响——一项在无肿瘤猪模型中评估的随机研究。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-24 DOI: 10.1007/s00280-025-04768-7
Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Christina Harlev, Elisabeth Krogsgaard Petersen, Hans Christian Rasmussen, Jakob Hansen, Thomas Baad Hansen, Akmal Safwat, Maiken Stilling
{"title":"Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations- a randomized study evaluated in a tumour-free porcine model.","authors":"Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Christina Harlev, Elisabeth Krogsgaard Petersen, Hans Christian Rasmussen, Jakob Hansen, Thomas Baad Hansen, Akmal Safwat, Maiken Stilling","doi":"10.1007/s00280-025-04768-7","DOIUrl":"10.1007/s00280-025-04768-7","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate plasma and bone- and soft-tissue concentrations of doxorubicin following two administrations of either bolus or continuous infusion administered at a three-week interval. The achievement of adequate concentration at target sites is believed to be positively correlated to effect, and it has been suggested that concentrations are affected by the number of administrations.</p><p><strong>Methods: </strong>Eighteen female pigs were included in the study and randomized into two groups of nine receiving either a bolus or continuous infusion. The animals received a dosage of 2 mg/kg on day 1 and on day 22. From day 1 to 10, doxorubicin concentrations, as well as kidney and liver function, were monitored with plasma samples (total concentrations). On day 22, doxorubicin was measured in plasma samples (total concentration) and microdialysates (unbound concentrations) from subcutaneous tissue, muscle, synovial fluid of the knee joint, cancellous bone, and intravenously.</p><p><strong>Results: </strong>On day 22, the pharmacokinetic profiles were comparable between the two groups except for plasma AUC<sub>0 - 12 h</sub>, which was higher after continuous infusion, and intravenous C<sub>max</sub>, which was higher after bolus infusion. Bone- and soft tissue concentrations were below 0.10 µg/mL. Except for mean plasma (total) concentration at the 6 h timepoint on day 1 and 22 in the continuous group, which was higher after the first administration (p = 0.037), no differences in plasma concentrations were found between the two administrations.</p><p><strong>Conclusion: </strong>Low mean tissue doxorubicin concentrations and similar pharmacokinetic profiles were found between the bolus and continuous infusion groups. Thus, similar anti-neoplastic efficacy is to be expected with both administration types.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"47"},"PeriodicalIF":2.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study. 贝伐单抗在日本蛋白尿癌症患者中的人群药代动力学分析:一项前瞻性队列研究。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-21 DOI: 10.1007/s00280-025-04769-6
Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Sho Masui, Daiki Hira, Marin Inoue, Kodai Yajima, Shunsaku Nakagawa, Yasuaki Ikemi, Junzo Hamanishi, Atsushi Takai, Shinya Yamamoto, Takeshi Matsubara, Masaki Mandai, Hiroshi Seno, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa
{"title":"Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study.","authors":"Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Sho Masui, Daiki Hira, Marin Inoue, Kodai Yajima, Shunsaku Nakagawa, Yasuaki Ikemi, Junzo Hamanishi, Atsushi Takai, Shinya Yamamoto, Takeshi Matsubara, Masaki Mandai, Hiroshi Seno, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa","doi":"10.1007/s00280-025-04769-6","DOIUrl":"10.1007/s00280-025-04769-6","url":null,"abstract":"<p><strong>Purpose: </strong>Bevacizumab (BV) is an effective therapeutic antibody utilized in various cancers. Serum BV concentration can be a factor that potentially affects its therapeutic efficacy. Although proteinuria could affect BV pharmacokinetics, its influence was not evaluated in the previous population pharmacokinetic (PopPK) studies. Because BV can cause proteinuria as an adverse event, the present study aimed to develop a PopPK model in patients with proteinuria and to evaluate the influence of proteinuria on BV pharmacokinetics.</p><p><strong>Methods: </strong>This prospective cohort study enrolled 70 Japanese cancer patients newly starting BV, and 368 concentration samples from these patients were analyzed. Serum BV concentrations were measured at several time points including at the onset of proteinuria. PopPK analysis was conducted using a non-linear mixed-effects modeling program. A two-compartment model was used to estimate total body clearance (CL).</p><p><strong>Results: </strong>Serum BV concentrations divided by the dose per body weight and dosing interval tended to be lower in patients with higher urinary protein to creatinine ratio (UPCR). The covariate analysis showed that increasing BV CL was associated with decreasing serum albumin concentration and increasing body weight and UPCR. The simulated median trough concentrations of BV in patients with Common Terminology Criteria for Adverse Events grades 1, 2, and 3 proteinuria were decreased by 12.0%, 20.6%, and 31.5%, respectively, compared to those in patients with grade 0.</p><p><strong>Conclusion: </strong>We successfully established a PopPK model incorporating UPCR to predict serum BV concentrations in patients with proteinuria. Our study provides additional insights to better understand BV pharmacokinetics.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"46"},"PeriodicalIF":2.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alternative routes of drug administration: exposure of imatinib using different formulations. 药物管理的替代途径:暴露伊马替尼使用不同的配方。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-20 DOI: 10.1007/s00280-025-04766-9
H B Fiebrich-Westra, O Visser, A B Francken, E J Smolders
{"title":"Alternative routes of drug administration: exposure of imatinib using different formulations.","authors":"H B Fiebrich-Westra, O Visser, A B Francken, E J Smolders","doi":"10.1007/s00280-025-04766-9","DOIUrl":"10.1007/s00280-025-04766-9","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the possibility of treating patients with alternative imatinib formulations.</p><p><strong>Methods: </strong>Two patients were treated with different enteral en rectal imatinib formulations. During treatment plasma concentrations where measured to assure adequate exposure.</p><p><strong>Results: </strong>The first patient received imatinib suspension through the duodenum tube. With a dose of 400 mg BID the patient had an imatinib plasma concentration of 750 µg/L. After increasing the dose to 600 mg BID the imatinib plasma concentration was 1500 µg/L (target GIST treatment > 1100 µg/L). Rectal administration of the tablet did not lead to sufficient plasma concentrations. The second had adequate exposure of imatinib both when the suspension was taken orally and through the tube (target CML treatment are > 1000 µg/L).</p><p><strong>Conclusion: </strong>For patients able to swallow liquids, we prefer the suspended imatinib tablets (comparable to drug label). If patients have a duodenum tube the use of a suspension base with pulverized tablets could be an alternative. Based on the extremely low exposure found in case 1, we do not recommend rectal administration of tablets. We recommend the monitor plasma concentrations when off label dosing forms are used.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"45"},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgement to reviewers 2023. 感谢审稿人2023。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-15 DOI: 10.1007/s00280-025-04762-z
{"title":"Acknowledgement to reviewers 2023.","authors":"","doi":"10.1007/s00280-025-04762-z","DOIUrl":"https://doi.org/10.1007/s00280-025-04762-z","url":null,"abstract":"","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"43"},"PeriodicalIF":2.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: HER-2 SMASH. 更正:HER-2 SMASH。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-13 DOI: 10.1007/s00280-025-04765-w
Celal Alandağ, Ayşegül Öztürk, Fatih Yulak, Zeynep Deniz Şahin İnan, Mustafa Özkaraca, Burak Batuhan Lacın, Ahmet Altun
{"title":"Correction: HER-2 SMASH.","authors":"Celal Alandağ, Ayşegül Öztürk, Fatih Yulak, Zeynep Deniz Şahin İnan, Mustafa Özkaraca, Burak Batuhan Lacın, Ahmet Altun","doi":"10.1007/s00280-025-04765-w","DOIUrl":"https://doi.org/10.1007/s00280-025-04765-w","url":null,"abstract":"","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"42"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid. 用亚叶酸逆转高剂量甲氨蝶呤细胞毒性的新建议。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-13 DOI: 10.1007/s00280-025-04749-w
Jesper Heldrup, Archie Bleyer, Laura Ramsey, Lauren Schaff, Brooke Bernhardt, Stefan Schwartz, Etienne Chatelut, Miriam Hwang, Carolina Ten, Martin Guscott, Scott Howard
{"title":"New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid.","authors":"Jesper Heldrup, Archie Bleyer, Laura Ramsey, Lauren Schaff, Brooke Bernhardt, Stefan Schwartz, Etienne Chatelut, Miriam Hwang, Carolina Ten, Martin Guscott, Scott Howard","doi":"10.1007/s00280-025-04749-w","DOIUrl":"10.1007/s00280-025-04749-w","url":null,"abstract":"<p><strong>Purpose: </strong>Folinic acid (FA) rescue protocols to counter the adverse effects of high-dose methotrexate (HDMTX) vary widely, and the risk of over-rescue and potential adverse effects of excessive FA (e.g., hypercalcemia) are under-recognized issues when providing augmented rescue in cases of delayed methotrexate elimination (DME). This opinion summary defines over-rescue, describes its potential adverse impacts, highlights the risk of hypercalcemia associated with excessive FA dosing in patients with acute kidney injury (AKI) from HDMTX, and provides recommendations to improve safety and efficacy of FA rescue in patients receiving HDMTX.</p><p><strong>Methods: </strong>A multidisciplinary panel of experts with clinical experience in HDMTX treatment convened in three roundtable meetings to coalesce expert opinion and best published evidence on the pharmacology and clinical effects and interactions of FA and HDMTX.</p><p><strong>Results: </strong>The type of FA (calcium folinate, calcium levofolinate, sodium levofolinate), dose, and frequency of FA administration may be factors for over-rescue and the development of hypercalcemia due to their respective pharmacokinetic characteristics, especially in cases of DME requiring augmented FA rescue.</p><p><strong>Conclusion: </strong>Clinicians are reminded of the possibility of over-rescue with FA and its impact on subsequent HDMTX courses, types of FA available and their durations of action, and avoid providing too frequent doses. In the setting of AKI and DME requiring high doses of FA, use of sodium levofolinate or calcium levofolinate may be considered to reduce the risk of hypercalcemia associated with calcium folinate.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"41"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature. 卡培他滨辅助治疗偶然诊断为肝内胆管癌的原位肝移植患者。DPYD多态性评估的意义:两例报告及文献复习。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-12 DOI: 10.1007/s00280-025-04756-x
Carolina Liguori, Simona Magi, Alessandra Mandolesi, Andrea Agostini, Gianluca Svegliati-Baroni, Andrea Benedetti Cacciaguerra, Alessandro Parisi, Elisa Tiberi, Marco Vivarelli, Andrea Giovagnoni, Gaia Goteri, Pasqualina Castaldo, Rossana Berardi, Riccardo Giampieri
{"title":"Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.","authors":"Carolina Liguori, Simona Magi, Alessandra Mandolesi, Andrea Agostini, Gianluca Svegliati-Baroni, Andrea Benedetti Cacciaguerra, Alessandro Parisi, Elisa Tiberi, Marco Vivarelli, Andrea Giovagnoni, Gaia Goteri, Pasqualina Castaldo, Rossana Berardi, Riccardo Giampieri","doi":"10.1007/s00280-025-04756-x","DOIUrl":"10.1007/s00280-025-04756-x","url":null,"abstract":"<p><p>In recent years, assessing dihydropyrimidine dehydrogenase (DPD) activity has become crucial for cancer patients undergoing 5-fluorouracil (5FU)-based chemotherapy due to the life-threatening toxicity associated with reduced DPD function. The methods for evaluating DPD activity have evolved, with the analysis of DPYD polymorphisms in blood samples becoming the preferred approach. As the indications for liver transplantation are increasing-particularly due to a rise in cases of cholangiocarcinoma (CCA) and non-resectable colorectal liver metastasis-more cancer patients with a history of liver transplantation may experience disease relapse. Furthermore, 5-fluorouracil chemotherapy is a standard treatment for both cancers. This growing need to evaluate DPD activity in transplanted livers arises because standard tests conducted on blood samples reflect the activity of native liver tissue and may produce misleading results. This paper presents two clinical cases from 2022 to 2023 involving patients who underwent successful liver transplants but were later diagnosed with intrahepatic CCA in the explanted liver. Both patients were subsequently prescribed capecitabine as adjuvant chemotherapy, making it essential to assess DPD activity in donor liver tissue to ensure safe treatment protocols. However, there are currently no established guidelines for this specific patient group. If we follow standard clinical practice, this critical analysis will be insufficient, as it only describes the DPD activity of the native liver. It is imperative to determine the DPD activity of the transplanted liver. In summary, this case report highlights the importance of managing this complex situation effectively.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"40"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). 替代剂量依鲁替尼对慢性淋巴细胞白血病(CLL)患者布鲁顿酪氨酸激酶(BTK)抑制作用的评价
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-02-28 DOI: 10.1007/s00280-025-04753-0
Aziz Ouerdani, Belén Valenzuela, Nicoline Treijtel, Nahor Haddish-Berhane, Sanjay Desphande, Srimathi Srinivasan, Emma Smith, Juan José Perez Ruixo
{"title":"Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).","authors":"Aziz Ouerdani, Belén Valenzuela, Nicoline Treijtel, Nahor Haddish-Berhane, Sanjay Desphande, Srimathi Srinivasan, Emma Smith, Juan José Perez Ruixo","doi":"10.1007/s00280-025-04753-0","DOIUrl":"10.1007/s00280-025-04753-0","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate alternative ibrutinib dosing regimens that maintain Bruton's tyrosine kinase (BTK) receptor occupancy over the entire dosing interval for CLL patients using a model-based approach.</p><p><strong>Methods: </strong>Ibrutinib inhibits B-cell proliferation via irreversible binding of BTK. As IC<sub>50</sub> is not an appropriate parameter to describe the potency of the inhibition in the presence of a covalent binding inhibitor. A BTK covalent binding model was developed using k<sub>inact</sub>/K<sub>I</sub> as key parameter to account for covalent binding. The ibrutinib-BTK covalent binding model was used to describe the effect of daily doses of 140, 280, 420 and 560 mg on the proportion of subjects with more than 90% BTK inhibition at steady state trough concentrations. Predictive performance of the model was assessed using the available ibrutinib BTK inhibition data following QD dosing. Model-based predictions were used to identify the minimum ibrutinib QD dose that provides more than 90% inhibition in more than 90% of the subjects.</p><p><strong>Results: </strong>The covalent binding model was able to describe the data and predicted that ibrutinib QD dose reduced from 420 mg to 280 mg or 140 mg may inhibit de novo synthetized BTK efficiently in a CLL population.</p><p><strong>Conclusion: </strong>Using a model-based approach showed that reducing the ibrutinib dosing regimen to 280 mg QD or even 140 mg in case of adverse events could maintain BTK inhibition over the entire dosing interval.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"38"},"PeriodicalIF":2.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. 建立阿西米尼的群体药代动力学模型,以支持慢性髓性白血病患者的暴露-反应和种族敏感性分析。
IF 2.7 4区 医学
Cancer Chemotherapy and Pharmacology Pub Date : 2025-02-28 DOI: 10.1007/s00280-025-04755-y
Christelle Darstein, Deokyong Yoon, Yiqun Yang, Shruti Kapoor, Kohinoor Dasgupta, Shengyuan Wu, Yasunori Kawakita, Matthias Hoch, Kai Grosch, Sherwin K B Sy
{"title":"Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.","authors":"Christelle Darstein, Deokyong Yoon, Yiqun Yang, Shruti Kapoor, Kohinoor Dasgupta, Shengyuan Wu, Yasunori Kawakita, Matthias Hoch, Kai Grosch, Sherwin K B Sy","doi":"10.1007/s00280-025-04755-y","DOIUrl":"10.1007/s00280-025-04755-y","url":null,"abstract":"<p><strong>Background: </strong>The original population pharmacokinetics (popPK) model for asciminib in patients with chronic myeloid leukemia in chronic phase (CML-CP) was refined to address drug development needs in support of drug submission, namely, attainment of target drug exposure in specific patient populations, populating individual daily exposures for exposure-response analyses of key efficacy and safety endpoints, confirmation of comparability in exposure between 40 mg b.i.d. and 80 mg q.d., and assessment of ethnic insensitivity.</p><p><strong>Methods: </strong>Participants from two organ dysfunction studies, patients with CML in blast and acute phases and acute lymphoblastic leukemia and patients from a phase III efficacy study in newly diagnosed Ph + CML-CP, and data from a dedicated phase II study in the Chinese patients previously treated with at least two prior tyrosine kinase inhibitors, and a phase IIIb study comparing two dose regimens of asciminib (40 mg b.i.d. and 80 mg q.d.) were included in the revised popPK model. Covariates evaluated were line of therapy, baseline renal and hepatic functions, Chinese or Japanese ethnicity.</p><p><strong>Results: </strong>The apparent clearance and steady-state volume of distribution of asciminib were 6.84 L/h and 110 L, respectively, for a typical individual of 70 kg weight and 90 mL/min absolute glomerular filtration rate. Both the 40 mg b.i.d. and 80 mg q.d. resulted in a steady-state daily AUC of 12,600 ng.h/mL, and there was no difference between lines of therapy. Effects of renal or hepatic impairment on clearance were not clinically relevant. Chinese and Japanese exhibited similar PK as that of the global population.</p><p><strong>Conclusions: </strong>The 40 mg b.i.d. and 80 mg q.d. regimens are comparable in their daily exposure, supporting the use of the two dosing regimens in newly diagnosed and previously treated CML-CP patients. The PK of asciminib is insensitive to ethnic differences and no dose adjustment is required for severe renal and hepatic impaired patients.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"39"},"PeriodicalIF":2.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信